KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$106.4 million.

  • CRISPR Therapeutics AG's Consolidated Net Income fell 2381.76% to -$106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$530.0 million, marking a year-over-year decrease of 9603.28%. This contributed to the annual value of -$408.0 million for FY2024, which is 12125.16% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Consolidated Net Income of -$106.4 million as of Q3 2025, which was down 2381.76% from -$208.6 million recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Consolidated Net Income registered a high of $759.2 million during Q2 2021, and its lowest value of -$208.6 million during Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's median Consolidated Net Income value was -$113.2 million (recorded in 2021), while the average stood at -$69.4 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Consolidated Net Income soared by 105287.85% in 2021 and then tumbled by 23481.09% in 2024.
  • CRISPR Therapeutics AG's Consolidated Net Income (Quarter) stood at -$141.2 million in 2021, then rose by 20.1% to -$112.9 million in 2022, then skyrocketed by 151.93% to $58.6 million in 2023, then tumbled by 234.81% to -$79.0 million in 2024, then plummeted by 34.71% to -$106.4 million in 2025.
  • Its Consolidated Net Income stands at -$106.4 million for Q3 2025, versus -$208.6 million for Q2 2025 and -$136.0 million for Q1 2025.